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Abstract
Purpose Traumatic spinal cord injury (SCI) is a devastating
condition which affects millions of people worldwide causing
major disability and substantial socioeconomic burden. There
are currently no effective treatments. Modulating the
neuroinflammatory (NI) response after SCI has evolved as a
major therapeutic strategy. PET can be used to detect the up-
regulation of the 18-kDa translocator protein (TSPO), a hall-
mark of activated microglia in the CNS. We investigated
whether PET imaging using the novel TSPO tracer [18F]GE-
180 can be used as a clinically relevant biomarker for NI in a
contusion SCI rat model, and we present data on the modula-
tion of NI by the lipid docosahexaenoic acid (DHA).
Methods A total of 22 adult maleWistar rats were subjected to
controlled spinal cord contusion at the T10 spinal cord level.
Six non-injured and ten T10 laminectomy only (LAM) ani-
mals were used as controls. A subset of six SCI animals were
treated with a single intravenous dose of 250 nmol/kg DHA
(SCI-DHA group) 30 min after injury; a saline-injected group
of six animals was used as an injection control. PET and CT
imaging was carried out 7 days after injury using the [18F]GE-
180 radiotracer. After imaging, the animals were killed and the
spinal cord dissected out for biodistribution and
autoradiography studies. In vivo data were correlated with
ex vivo immunohistochemistry for TSPO.
Results In vivo dynamic PET imaging revealed an increase in
tracer uptake in the spinal cord of the SCI animals compared
with the non-injured and LAM animals from 35 min after
injection (P < 0.0001; SCI vs. LAM vs. non-injured).
Biodistribution and autoradiography studies confirmed the
high affinity and specific [18F]GE-180 binding in the injured
spinal cord compared with the binding in the control groups.
Furthermore, they also showed decreased tracer uptake in the
T10 SCI area in relation to the non-injured remainder of the
spinal cord in the SCI-DHA group compared with the SCI-
saline group (P<0.05), supporting a NI modulatory effect of
DHA. Immunohistochemistry showed a high level of TSPO
expression (38 %) at the T10 injury site in SCI animals com-
pared with that in the non-injured animals (6 %).
Conclusion [18F]GE-180 PET imaging can reveal areas of
increased TSPO expression that can be visualized and quan-
tified in vivo after SCI, offering a minimally invasive ap-
proach to the monitoring of NI in SCI models and providing
a translatable clinical readout for the testing of new therapies.
Keywords Spinal cord injury . Neuroinflammatory respone .
[18F]GE-180 . Rat model . Docosahexaenoic acid
Introduction
Traumatic spinal cord injury (SCI) is a devastating condition,
affecting around 2.5 million people worldwide [1]. It has a
substantial impact on individuals and carers, and is associated
with a major socioeconomic cost [2]. There are currently no
effective treatments, either in the acute or the chronic phase of
SCI. Currently, the follow-up and prognosis of SCI patients is
based on clinical assessments of motor and sensory function.
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There is a need for new approaches to assess the evolution of
the condition in vivo, and in particular translational ap-
proaches which can directly link the clinic to research in ex-
perimental SCI models used for the testing new therapies.
Most of the biomarkers reported in SCI patients assess struc-
tural changes associated with tissue damage, e.g. compounds
such the glial protein S-100B [3] or neurofilaments [4], but do
not appear to provide a sensitive prognosis for clinical use [5].
Imaging technologies can provide noninvasive tools for eval-
uating SCI [6, 7]. MRI is currently considered the standard
approach for the prognostication of acute SCI [8] and more
recently, the use of functional nuclear imaging approaches has
been providing new targets for assessing the inflammatory
and metabolic changes in the central nervous system (CNS),
providing new perspectives on the pathophysiology of
neurotrauma [9].
Traumatic SCI is associated with activation of glial cells,
which is a general index of neuroinflammation (NI) [10]. The
NI response after SCI is complex and multiphasic [11, 12].
The neuroplasticity-inhibiting environment driven by a persis-
tent NI response after injury could potentially be a major ther-
apeutic target [13]. Therefore, in vivo imaging of the NI re-
sponse after SCI is a desirable target for the diagnosis and
monitoring of disease progression, and also for testing thera-
peutic effects, in preclinical studies and in patients [14]. The
most established and characterized biomarker for in vivo im-
aging of NI is the 18-kDa translocator protein (TSPO) [15,
16]. TSPO is a cholesterol-transport protein which is present
in the outer mitochondrial membrane of cells throughout the
body [17]. Upregulation of TSPO expression has been asso-
ciated with glial cell activation following CNS injury and
inflammation in various CNS disorders [18]. Several PET
tracer ligands for TSPO, including [11C]-R-PK11195 [19,
20], [11C]PBR28 [21, 22] and [18F]DPA714 [23], have been
investigated in both animals and humans for CNS imaging
and in some studies tracers have been directly compared [23,
24]. The various tracer ligands have different characteristics in
terms of sensitivity, in vivo stability and specificity of binding.
Due to the potential of TSPO as a NI imaging biomarker, there
is significant effort to develop better tracers and also test iso-
topes with longer half-lives, such as 18F, which may also
favourably affect the logistics for PET imaging. The second-
generation TSPO tracer, [18F]GE-180 has been shown to bind
selectively with high affinity to TSPO [25].
TSPO imaging of the spinal cord (normal or injured) in
small experimental animals poses anatomical and technical
challenges, due to the small size of the spinal cord, its location
along the vertebral column and also its proximity to many
other highly metabolic organs (e.g. liver, kidneys and heart)
which also show a very high uptake of TSPO tracers. It is
important to investigate the signal given by a TSPO tracer in
experimental SCI models in order to support its potential
translation to clinical use in SCI. In this study we investigated
NI after SCI using in vivo PET imaging in a rat SCI model
with the novel TSPO tracer [18F]GE-180 which has been
proven to have improved imaging characteristics with higher
binding potential and lower nonspecific binding when com-
pared to PK11195 in various models of CNS injury [26–28].
We combined imaging with ex vivo autoradiography and im-
munohistochemistry in order to fully characterize the potential
of the ligand to detect NI in the injured spinal cord.
Furthermore, to investigate its clinical value we also tested
its sensitivity for monitoring the therapeutic effects of
docosahexaenoic acid (DHA), an ω-3 polyunsaturated fatty
acid which is known to act as a powerful neuroprotective
agent in rat SCI modulating the inflammatory response asso-
ciated with tissue injury [29–32].
Materials and methods
Animal procedures
Male adult Wistar rats weighing 265±35.4 g were obtained
from Charles River Laboratories (Charles River, UK). All
animal procedures were approved by the Animal Welfare
and Ethical Review Body at Queen Mary University of
London, and the UK Home Office, in accordance with the
EU Directive 2010/63/EU.
SCI surgery The spinal cord was injured at vertebral thoracic
level 10 (T10) in accordance with a previously established
contusion model in rats [33]. Animals were anaesthetized by
intraperitoneal injection of a mixture of ketamine (50 mg/kg)
and medetomidine (0.2 mg/kg) in sterile saline. Following the
onset of anaesthesia, the most prominent spinous process in
the thoracic spine was identified and marked, as it is typically
the T10 spinous process. The area was shaved and cleaned
with iodine. A midline incision was performed centred on the
T10 mark, and the fascia and muscle layers were pulled away
from the T9–T11 spinous processes and laminae. The T9 and
T11 lateral aspects of the vertebral body spinous processes
were clamped to stabilize any movement of the spinal cord.
A bilateral laminectomy was performed at T10, leaving the
dura exposed but intact. After securing the spinal column, a
PCI3000 Precision Cortical Impactor™ (Hatteras
Instruments, Cary, NC) was used with the following settings:
impactor tip 2 mm, impact speed 1.5 m/s, depth 1.8 mm and
dwell time 100 ms. The muscle and fascia layers were then
sutured and the skin was closed. Thirty minutes after contu-
sion, a cohort of animals received an injection via a tail vein of
either vehicle (0.001 % ethanol in saline) or DHA (Sigma
D2534, 250 nmol/kg), in a volume of 5 ml/kg. The DHA dose
chosen was based on the findings of previous studies from our
laboratory showing functional improvements in SCI rats fol-
lowing DHA treatment [34]. Control animals were either
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noninjured (naive) or subjected to a laminectomy only
(LAM).
All animals were considered to have undergone a success-
ful contusion injury as shown by a complete loss of reflex
responses and hind limb movement. During the recovery
phase animals had access to food and water ad libitum and
were housed under a 12-h light/dark cycle. All animals re-
ceived a subcutaneous injection of 0.01 mg/kg buprenorphine
(Reckitt Benckiser, Slough, UK) for pre-emptive analgesia
followed by postoperative dosing together with saline subcu-
taneously twice daily for 3 days after surgery. Bladders were
manually expressed twice a day until return of bladder func-
tion (<2 ml of urine in early morning expression for three
consecutive days).
For study 1 on the use of TSPO for imaging the injured
spinal cord, three experimental groups were set up: SCI group
(ten animals), LAM group (eight animals) and naive group
(six animals). For study 2 on the use of TSPO to detect ther-
apeutic effects, two experimental groups were set up: SCI-
DHA group (six animals) and SCI-saline group (six animals).
(For study design see Supplementary Fig. 1a).
Behavioural testing
All behavioural testing and data analysis were performed
blind by the experimenter. Open field locomotion assessment
using the Basso, Beattie, Bresnahan (BBB) Locomotor Rating
Scale [35] was carried out once on day 6 or day 7 to charac-
terize the functional outcome after spinal contusion in the SCI
groups (SCI, SCI-DHA and SCI-saline) compared with the
LAM group and naive group.
Tracer production
[18F]GE-180 was prepared by direct nucleophilic [18F] fluori-
nation of its corresponding mesylate precursor. The prepara-
tion was performed on a GE FASTlab™ synthesizer with
cartr idge SPE purif icat ion and formulation [36].
Radiochemical purity was 96±1 % (seven production runs)
and the specific activity was 175±38 GBq/μmol (seven pro-
duction runs) at the end of synthesis (see Supplementary
Fig. 2).
In vivo imaging
In vivo PET and CT scans were performed using a Siemens
INVEON® PET/CT scanner (Siemens Preclinical Solutions,
Knoxville, TN). On day 7 after surgery, animals were anaes-
thetized with isoflurane (5 % induction, then reduced to 1.5–
2 % for maintenance in 0.5 L/min air) during animal prepara-
tion and scanning. A tail vein was cannulated for tracer injec-
tion (injected dose, ID, 25.4±2.4 MBq, mass dose 1.9±0.1
µg/ml per animal; see Supplementary Fig. 1b, c and Fig. 2)
and the animal was immediately transferred to the scanner for
imaging. The animals were placed prone on a heating pad to
maintain a body temperature of 37 °C. Respiration was mon-
itored throughout the scan. Due to the equipment set-up, dos-
ing was done outside the scanner (Inveon Acquisition
Workplace 2.0) and then approximately 5 min after tracer
injection, a 60-min dynamic PET scan was started (matrix
128 × 128 × 161, pixel size 0.77 mm, slice thickness
0.106 cm). Immediately after the PET acquisition, a CT scan
(spatial resolution 113 μm, 80 kV, 500 μA) was performed to
correct for signal attenuation and anatomical references.
PET/CT data analysis
Emission scans were analysed as total (60 min) and dynamic
(12 frames×5 min) emission data, normalized and corrected
for attenuation, scattering and radioactivity decay, and recon-
structed using the OSEM 3D iterative protocol from the
Inveon™ Research Workplace (IRW 4.0) software (Siemens
Medical Solutions). Images were then evaluated and specific
uptake was assessed by drawing circular volumes of interest in
the T10 spinal cord segment, avoiding the vertebral canal and
using as controls the spinal cord areas within the cervical,
thoracic and lumbar areas and also in the brain and biceps
muscle. Tracer uptake (%ID/g) was calculated using the
volume of interest analysis using the IRW 4.0 software. For
study 1, the animals imaged included SCI group, the LAM
group and the naive group (data from two animals were not
used due to PET/CTsystem failure following tracer injection),
and in study 2 the animals imaged included the SCI-DHA
group and the SCI-saline group.
Biodistribution
Immediately after PET/CT imaging some of the anaesthetized
rats (see Supplementary Fig. 1a) were killed with sodium phe-
nobarbital (50 mg/kg, intraperitoneal) and the following tissue
samples were collected: blood, heart, lung, salivary glands,
spleen, adrenal glands, kidneys, quadriceps muscle, brain
and cerebellum. The spinal cord was dissected out, separating
the T9–T11 region from the non-injured regions. Each sam-
ple was weighed and counted in a γ-counter (LKB
Compugamma) along with dose standards. The percentage
of ID per gram of tissue was calculated for each tissue and
data were normalized for activity decay and the ID.
Ex vivo autoradiography
In a cohort of animals (LAM group, three animals; naive
group, five animals; SCI-DHA group, six animals, and SCI-
saline group, six animals), the whole spinal cord was freshly
dissected out from the vertebral column immediately after
imaging and fully exposed to a digital autoradiography x-ray
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film cassette for 30 min. Films were scanned with a Cyclone
phosphorimager and the region of interest (ROI) data analysed
using the proprietary integral OptiQuant software. Data are
expressed as digital light units (DLU) per millimetre squared,
normalized to the ID ([DLU/mm2]× ID). Dilution standards of
the tracer doses were used as reference for quantification.
Histology
On day 7 after injury, the rats were deeply anaesthetized with
sodium pentobarbital (50 mg/kg, intraperitoneal; Sagatal,
Rhone Merieux, Harlow, UK) and transcardially perfused
with 4 % paraformaldehyde (PFA) in 0.1 M phosphate-
buffer saline (PBS), pH 7.4. Spinal cords were dissected out,
postfixed in 4 % PFA for 2 h, and cryoprotected in 20 %
sucrose in 0.1 M PBS at 4 °C until further processing. A 10-
mm segment of the spinal cord containing the contusion injury
site in the centre was dissected out and embedded in OCT
medium and sectioned using a cryostat. Serial 20-μm longitu-
dinal sections, all across the whole thickness of the spinal
cord, were cut and mounted onto Superfrost Plus slides.
Randomly selected spinal cord sections from the study 1 SCI,
LAM and naive animals and from the study 2 SCI-DHA and
SCI-saline animals (three animals per group, three sections per
animal; see Supplementary Fig. 1a) were processed for immu-
nohistochemistry using the following primary antibodies: rabbit
anti-TSPO antibody (1:1,000; Novus Biologicals, Abingdon,
UK) for TSPO [37], mouse monoclonal anti-glial fibrillary acid-
ic protein (GFAP) antibody (1:800; Millipore, Temecula, CA)
for astrocytes, and goatmonoclonal anti-ionized calcium binding
adaptor molecule 1 (Iba1) antibody (1:800; Abcam, Cambridge,
UK) for microglia. Sections were incubated in 5 % normal don-
key serum for 30 min, followed by overnight incubation with
primary antibodies at 4 °C in a wet chamber. Sections were
washed three times with PBS before incubation for 2 h in the
secondary antibodies, either donkey anti-mouse for GFAP
(1:200; Alexa Fluor 568, Oregon, USA), or donkey anti-goat
for Iba-1 (1:200; Alexa Fluor 594, Oregon, USA).
Tyramide signal amplification was performed for detection
of TSPO. Sections were incubated with biotinylated goat anti-
rabbit antibody (1:1,000, Vector BA-1000; Vector
Laboratories, Peterborough, UK). After three further washes
with PBS, sections were incubated with the Vectastain® ABC
reagent (avidin-biotin-peroxidase complex; 1:250 solution A
and 1:250 solution B in PBS; Vector Laboratories) for 30 min
at room temperature. Following three washes, sections were
incubated with biotinyl tyramide (Perkin Elmer, Waltham,
MA) diluted in amplification diluent (1:75) for 10 min. After
a further three 5-min washes with PBS, the sections were
incubated with extra-avidin FITC (1:400, E2761; Sigma) for
2 h. Finally after three washes with PBS, the sections were
then counterstained with the fluorescent nuclear dye bis-
benzimide (Hoechst 33342, 1 μg/ml PBS; Sigma) for
10 min, followed by a 10-min wash with PBS and then
mounted and coverslipped using Vectashield fluorescent
mounting medium (H-1000; Vector Laboratories,
Burlingame, CA).
Histology image capture and analysis
Image analysis and quantification were performed with the
observer blinded to the group assignment. Three sections per
animal were stained for TSPO, Iba-1 and/or GFAP. At least
eight fields were viewed and captured per section, with four
fields selected around the edge of the injury site and two fields
selected rostrally and caudally to the injury site. Images were
viewed at ×400magnification and photographed using a Zeiss
Axioskop 2 microscope equipped with a Hamamatsu digital
camera (C4742-95), and stored using HiPic version 9.1 soft-
ware. Immunoreactivity quantitative analysis was carried out
using the ImageJ analysis program (ImageJ 1.48; National
Institutes of Health) and using a specific ImageJ script (JVP
AutoColourCellCountsRev). The specific fluorescent signals
emitted under different excitation lasers were selected by
thresholding and then superimposed on the thresholded nuclei
area to measure cellular immunoreactivity colocalization. The
level of immunoreactivity was expressed as the percentage of
the area of the measuring frame that contained immunoreac-
tivity. A Zeiss LSM 710 confocal microscope was used for
further detailed histological characterization and acquisition
of images (ZEN lite software; Zeiss, Cambridge, UK).
Statistical analysis
[18F]GE-180 uptake values were compared using one-way
ANOVA (treatment effect on the total uptake summed after
the 1-h PET acquisition) or two-way ANOVA (treatment and
time effect on dynamic uptake during the 1-h PETacquisition)
with Tukey’s multiple comparison test to compare every mean
uptake value at each time-point. BBB behaviour scores,
biodistribution and autoradiography data were analysed using
Student’s t test for paired data or one-way ANOVA for
grouped data. Immunohistochemistry data quantified using
ImageJ software were analysed using a one-way ANOVA
followed by Tukey’s multiple comparisons. Statistical analy-
sis was performed using GraphPad PRISM 5.0 software
(GraphPad, La Jolla, CA) and differences at the 95 % confi-
dence level (P<0.05) were considered significant.
Results
Assessment of the functional outcome after contusion SCI
After injury, the BBB scores showed a severe locomotor im-
pairment in SCI animals (score 6.3 ± 0.5; P<0.001) while
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normal locomotion was observed in the LAM and the naive
animals (score 21±0 for both groups; Table 1). In the DHA
study, treatment with DHA after injury led to a marked im-
provement in locomotor outcome: the SCI-DHA animals had
a BBB score of 5.3±0.6 compared with 1.8±0.6 in the SCI-
saline animals (P<0.001; Table 1).
In vivo imaging
First, cumulative [18F]GE-180 uptake during the 1-h PET ac-
quisition was assessed. As shown in Fig. 1a (study 1, effect of
injury), there was a significantly higher uptake in the SCI
animals than in the LAM and naive animals in the ROI in
the T10 region of the spinal cord (injury target) (0.55
± 0.2 %ID/g for the SCI group vs. 0.35 ± 0.2 and 0.29
±0.06 %ID/g for the LAM and naive groups, respectively;
P=0.03; Fig. 1b). Such differences in uptake between groups
in the T10 region were not detected in any other selected ROIs
across the rest of the spinal cord and brain, or in the muscle
(Fig. 1c).
To better characterize the dynamics of [18F]GE-180 up-
take, 60-min dynamic emission scans with 5 min per frame
were carried out. Scans were started 5 min after tracer injec-
tion, hence missing the initial zero condition. As shown in
Fig. 2a, there was significantly higher uptake in the SCI ani-
mals than in the LAM and naive animals in the T10 spinal
cord ROIs. At 30 min acquisition time (around 35 min after
tracer injection), the [18F]GE-180 uptake in the T10 ROIs in
SCI animals was significantly higher than in the naive animals
(0.56±0.04 %ID/g for the SCI group vs. 0.023±0.02 %ID/g
for the naive group at 30 min; 0.59±0.05 %ID/g for the SCI
group vs. 0.023±0.02 %ID/g for the naive group at 60 min;
P<0.05; Fig. 2b). There was also significantly higher uptake
in the SCI animals than in the LAM and naive animals in the
time-frames 35–40 min and 55–60 min (0.59±0.05 %ID/g
for the SCI group vs. 0.4±0.07 %ID/g for the LAM group at
35 min; 0.59 ± 0.05 %ID/g for the SCI group vs. 0.39
± 0.07 %ID/g for the naive group at 60 min, P < 0.05;
Fig. 2b), confirming the specific enhanced [18F]GE-180
uptake in the T10 ROI of the injured spinal cord. No differ-
ences in uptake were detected in the T10 ROI between the
laminectomy and naive groups in any time-frame. No differ-
ences in uptakewere detected in any of the groups in any time-
frame in muscle (baseline measurement).
In study 2 assessing changes in TSPO after SCI followed
30 min later by treatment with DHA, overall both the cumu-
lative update data and the time-frame analysis showed that the
treatment induced a trend towards a decrease in tracer uptake
(Fig. 3). However, the effect was not statistically significant.
Thus, no significant differences in cumulative [18F]GE-180
uptake were seen in the T10 ROI spinal region between the
SCI-DHA group and the SCI-saline group during the 1-h PET
acquisition on day 7 after injury (Fig. 3a). Similarly, no dif-
ferences in uptake were seen in the 60-min dynamic emission
scans with 5-min frame acquisitions (Fig. 3b, c). The trend
towards a decrease after DHA treatment was also detected in
the other selected ROIs across the rest of the spinal cord and
the brain (see Supplementary Fig. 3).
Biodistribution and autoradiography after in vivo PET
imaging
The biodistribution of [18F]GE-180 in the SCI animals
assessed after PET imaging showed significantly higher up-
take in the T10 spinal cord area tissue than in the rest of the
spinal cord tissue (0.85±0.3 %ID/g vs. 0.25±0.04 %ID/g,
respectively, P=0.02; Fig. 4a). No such difference was seen
in the spinal cord tissues dissected from the LAM and naive
animals (0.2±0.06%ID/g vs. 0.19±0.06%ID/g, respectively,
in the LAM group; 0.2±0.04 %ID/g vs. 0.2±0.02 %ID/g,
respectively, in the naive group; Fig. 4a). The tracer
biodistribution in other body tissues/organs did not show no-
table differences (see Supplementary Fig. 4a). Interestingly,
there was lower uptake in the T10 SCI area in the SCI-DHA
animals than in the SCI-saline animals, but there was no sig-
nificantly different uptake between the T10 area and the other
non-injured spinal cord tissue (0.4 ± 0.06 %ID/g vs. 0.3
±0.05 %ID/g, respectively, in the SCI-DHA group, P=0.1;
0.5 ± 0.13 %ID/g vs. 0.2 ± 0.08 %ID/g, respectively, in the
SCI-saline group, P=0.04). The tracer biodistribution in other
body tissues/organs did not show notable differences, except
for higher uptake in the adrenal glands of the SCI-DHA ani-
mals (7.3 ± 1.5 %ID/g in the SCI-DHA group vs. 4.2
± 0.8 %ID/g in the SCI-saline group, P = 0.01; see
Supplementary Fig. 4b).
Figure 5a shows typical autoradiography images of the
dissected spinal cords after [18F]GE-180 CT data analysis im-
aging. There was preferential accumulation of radioactivity in
the T10 SCI area compared with the accumulation in rest of
the non-injured spinal cord 7 days after injury, and compared
with the accumulation in the spinal cords of the LAM and
naive animals. Quantitative analysis of the autoradiographs
Table 1 BBB behaviour scores acquired once on day 6 or day 7 after
injury and before PET imaging
Study Group No. of animals BBB score
1 (effect of injury) SCI 10 6.3 ± 0.5*
LAM 8 21± 0
Naive 6 21 ± 0
2 (effect of DHA) SCI-DHA 6 5.3 ± 0.6**
SCI-saline 6 1.8 ± 0.6
The BBB scores are presented are means ± SEM
*P< 0.05, one-way ANOVA
**P< 0.05, t test
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confirmed the significantly higher uptake of [18F]GE-180 in
the T10 ROI of the SCI-saline animals compared with uptake
in the SCI-DHA, LAM and naive animals (P=0.01, one-way
ANOVA with Tukey’s multiple comparisons; 2.6 ± 0.9 %
DLU/mm2 per ID in the T10 spinal cord area in the SCI-
saline animals vs. 0.2±0.2 % DLU/mm2 per ID in the naive
animals). Despite the lack of a statistically significant differ-
ence in tracer accumulation in the T10 injured spinal cord
between the SCI-saline and SCI-DHA animals, an overall
lower uptake was observed in the SCI-DHA animals (0.7
*+
*+* *
*+
**
*+
[18F]GE-180
a
b
Fig. 2 Time–activity curves of [18F]GE-180 uptake over the 1-h PET
acquisition starting 5 min after injection (study 1). a Higher uptake in the
T10 spinal cord ROI (Injury T10) compared with uptake in the brain and
biceps muscle ROIs in SCI animals (n= 8), laminectomy (LAM) animals
(n = 6) and naive animals (n = 4) on day 7 after surgery. b Higher uptake
(two-way ANOVA P< 0.0001) in the T10 spinal cord ROI area in the
SCI, LAM and naive animals; Tukey’s multiple comparison test between
the groups showed a significantly higher uptake at specific acquisition
times in the SCI group than in the control groups (*SCI vs. naïve, +SCI
vs. LAM); there were no differences in uptake between the LAM and
naive groups. The data are presented as means ± SEM (%ID/g)
a b
c
Contusion SCI-T10 7 days post surgery
Laminectomy-T10 7 days post surgery
Fig. 1 PET/CT imaging. a Representative PET/CT 3D MIP images in
rats acquired on day 7 after SCI or laminectomy only, with higher
magnification axial, coronal and sagittal 2D PET/CT images in the T10
spinal cord. Note the enhanced signal contrast in the SCI animal
compared with the laminectomy only animal. b Quantification of the
total cumulative [18F]GE-180 uptake in the T10 ROI during the 1-h
PET acquisition shows significantly higher uptake in the SCI group
(n= 10) than in the laminectomy group (LAM; n = 6) and naive group
(n = 4). c Quantification of the total cumulative [18F]GE-180 uptake
during the 1-h PET acquisition shows higher uptake in the T10 ROI of
SCI animals than in the ROIs of other areas (cervical, thoracic excluding
the T10 area and lumbar areas, brain and biceps muscle). Data are
presented as means ± SEM (%ID/g); P< 0.05, one-way ANOVA with
post-hoc analysis ()
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±0.5 % DLU/mm2 per ID in the SCI-DHA animals vs. 2.6
± 0.9 % DLU/mm2 per ID in the SCI-saline animals). A
similar trend in tracer uptake was also seen in the other spinal
cord non-injured areas (see Supplementary Figs. 4 and 5).
a b
c
%
 ID
/g
[18F]GE-180 uptake at T10
Fig. 3 [18F]GE-180 uptake during PET acquisition (study 2: effect of
DHA treatment). a Total cumulative uptake in the T10 ROI during the
1-h PET acquisition shows no significantly different uptake on day 7
between SCI animals treated with DHA (n= 6) and SCI animals treated
with saline (n= 5) 30 min after injury (t test, P= 0.2). b Dynamic uptake
in the T10 ROI in SCI animals treated with DHA and SCI animals treated
with saline. No statistically significant difference was seen despite a trend
towards a lower tracer uptake in DHA-treated animals (two-way
ANOVA; P= 0.1 DHA treatment effect; P= 0.3 acquisition time effect).
c Higher dynamic uptake in the T10 ROI (Injury T10) than in the brain
and the biceps muscle ROIs over 60 min in SCI animals treated with
DHA (n = 6) and SCI animals treated with saline (n= 5) on day 7 after
the intervention. The data are presented as means ± SEM (%ID/g)
a bBiodistribution Study 1 (Injury Effect) Biodistribution Study 2 (DHA  effect)
*(P<0.05)
SCI-D7  LAM-D7 Naive
* (P<0.05)
NS(P=0.1) 
SCI-D7 DHA treated SCI-D7 Saline treated
Fig. 4 [18F]GE-180 in vivo biodistribution after the 1-h PET acquisition
in the spinal cord (injured T10 area vs. non-injured areas rostral and
caudal to the T10 region). a Study 1 (effect of injury): Higher uptake in
the T10 area than in the non-injured areas rostral and caudal to T10 in SCI
animals on day 7 after injury (n = 10; t test; P= 0.02). There were no
differences in uptake in the spinal cord in LAM animals (n = 8) and
naive animals (n= 6). b Study 2 (effect of DHA treatment): SCI-saline
animals showed significantly higher uptake in the T10 SCI region than in
the regions rostral/caudal to T10 (P= 0.04) on day 7 after injury, but the
SCI-DHA animals (n = 6) showed no significant difference in uptake
between the T10 SCI region and the regions rostral/caudal to T10 (t test,
P= 0.01) on day 7 after injury. The data are presented as means ± SEM
(%ID/g)
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Immunohistochemistry analysis
Immunohistochemistry analysis showed a significant increase
in TSPO-expressing cells at the T10 injury site in the SCI
animals compared with the LAM and naive animals, both
around the injury site and in the areas rostral and caudal to
the injury site. The percentages of TSPO-expressing cells
were 38.24 ± 4.1 in the SCI animals vs. 29.29 ± 1.9 in the
LAM animals (P<0.05) and vs. 6.4±2.7 in the naive animals
(P<0.0001) for the injury area, and 16.9±4.1 in the SCI an-
imals and 19.4±4.3 in the LAM animals vs. 5.9±2.7 in the
naive animals (P<0.0001) for the rostral and caudal areas
(Fig. 6a). Iba-1 and GFAP immunolabelling to characterize
the glial response across the injured spinal cord sections
showed a significant increase in Iba-1-expressing cells
(microglia) in the SCI animals compared with the LAM and
naive animals at the T10 injury site (Iba-1 expressing cells
52.8 ± 3.8 % in the SCI animals vs. 32.5 ± 3.17 % in the
LAM animals and 31.3 ± 4.6 % in the naive animals;
P<0.0001; Fig. 6b).
There were no differences in the proportions of GFAP-
expressing cells (astrocytes) between the T10 SCI area and
the areas caudal and rostral to the injury site (Fig. 6c). TSPO
immunolabelling was detected at the edge of the lesion site
and also in the areas dorsal and caudal to the injury site in the
SCI animals, but was not detected in the naive animals
(Fig. 7a, b, Supplementary Fig. 6). In the SCI animals, Iba1
and GFAP immunolabelling of the glial scar showed a clear
area devoid of signal at the centre of the lesion (Fig. 7a), with a
dense pattern of microglia detected at the edges of the lesion
core tissue with the astrocytes forming a well-defined scar
border (Fig. 7b). Amoeboid and less-ramified microglia were
detected at the lesion edges displaying TSPO expression
(Fig. 7a, insets a, b). But away from the lesion edges, microg-
lia showed a more ramified morphology with no
colocalization of Iba1 and TSPO expression (Fig. 7a, inset
c). However, TSPO-expressing cells were clearly detected in
the regions caudal and rostral to the lesion core (Fig. 7a, ar-
rowheads and inset c). TSPO immunolabelling was also ap-
parent within the damaged core tissue above the astrocytic
scar (Fig. 7, inset d). Tissue from SCI-DHA animals showed
a significant decrease in the percentage of TSPO-expressing
cells in the injury centre comparedwith the SCI-saline animals
(25.9±4.5 % in SCI-DHA animals vs. 40.19±6.7 % in SCI-
saline animals; P=0.03).
Discussion
This study used combined PET data analysis/CT imaging to
visualize for the first time in vivo an index of the NI response
in adult SCI rats and its modulation by a neuroprotective treat-
ment. Targeting the upregulation of TSPO expression as a
surrogate inflammation biomarker for CNS injury enables
for the first time the selective identification of such specific
NI events in an anatomically challenging injury site in a living
animal model. The novel [18F]GE-180 tracer, with high spe-
cific binding to TSPO as shown in other CNS inflammatory
models [26–28], showed differential uptake in the T10
contused SCI tissue that could be visualized and quantified
in vivo, compared with the corresponding area in non-SCI
animals (42 % tracer uptake increase in SCI compared with
non-SCI animals). Despite the increased TSPO signal associ-
ated with other organs with high metabolism, such as the
heart, kidneys and adrenal glands [15, 38] and the in situ
upregulation of TSPO associated with the bone inflammatory
Naïve
Laminectomy D7
SCI D7
T10 area
a b
Autoradiography of dissected spinal cords 1 h post [18F]GE180 injection
* (P<0.05)
Fig. 5 Autoradiography of dissected spinal cords 1 h after [18F]GE-180
PET. a Representative autoradiographs fully dissected spinal cords show
high specific binding of [18F]GE-180 in the T10 area in a SCI animal
7 days after injury, in contrast to the low/absent binding in the T10 areas
in naive and LAManimals. bQuantitative analysis of the autoradiographs
shows a significant effect of SCI and DHA treatment on [18F]GE-180
binding in the T10 ROIs in the SCI-saline, SCI-DHA, LAM and naive
animals. The data are presented as means ± SEM (one –way ANOVA,
*P= 0.01)
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response [34] induced by the laminectomy procedure, the PET
data analysis data clearly showed higher specific uptake in the
T10 SCI tissue than in the rest of the non-contused spinal cord.
The use of combined PET data analysis/CT imaging facil-
itated dynamic visualization of the in vivo biodistribution and
binding of the injected tracer at the injury site, in accordance
with similar trends shown in other CNS injury models [26,
27], despite missing the initial activity peak due to our setting
limitations for injecting the animals in the scanner. The find-
ings were supported by the tracer accumulation detected
a b
c
d
Fig. 6 Immunohistochemical analysis of the spinal cord of SCI, LAM
and naive animals (study 1) and SCI-DHA and SCI-saline animals (study
2; three animals per group) on day 7 after the intervention. The data
presented are as the average percentages of cells displaying TSPO, Iba-
1 or GFAP immunolabelling around the T10 injury area from fields of
view (FOVs) c1 + c2+ c3+ 4, and in the areas rostral and caudal to the
T10 injury site are the average percentages from FOVs d1+ d2+ d3+ d4.
a The percentage of TSPO-expressing cells is significantly higher in the
T10 injury area in the SCI animals compared with the LAM and naive
animals. b The percentage of Iba-1-expressing cells is significantly higher
in the T10 injury site in the SCI animals compared with the LAM and
naive animals. c The percentage of GFAP-expressing cells does not differ
among the three groups for either T10 injury site or the areas rostral and
caudal to the injury site. d The percentage of TSPO-expressing cells is
significantly lower in the T10 injury area in the SCI-DHA animals than in
the SCI-saline animals. The data are presented as means ± SEM (one
way-ANOVA with Tukey’s multiple comparisons; *P < 0.05,
**P< 0.0001)
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ex vivo in dissected spinal cord after PET data analysis imag-
ing, showing a significant increase in uptake in the T10 region
compared with the rest of the non-injured spinal cord tract in
SCI animals, and compared with LAM and naive animals.
The in vivo differential uptake was also confirmed by the
autoradiography analysis, that clearly showed the specific up-
take of [18F]GE-180 in the injured T10 region in contrast to
that seen in the LAM and naive animals. Furthermore, the
upregulation of TSPO expression in the injured spinal cord
was also confirmed by immunohistochemistry, that showed
higher TSPO expression at the injury site in SCI animals (38
vs. 6 % in naive animals). Such increases in TSPO
immunolabelling were similar to the increase in activated
Iba-1-expressing amoeboid microglia at the edges of the inju-
ry site, which also showed TSPO immunolabelling. This sup-
ports the findings of previous studies in other disease models
validating the use the TSPO signal in activated microglia as a
biomarker of inflammation [18, 39].
The data obtained in this study support the diagnostic
value of using TSPO for in vivo imaging to monitor the on-
going NI process in the injured spinal cord, despite the small
diameter (3–4 mm) of the injured spinal cord and the marked
peripheral inflammation occurring in the nearby injured ver-
tebrae and non-neural tissue. Previous studies have shown
increased uptake of fluorodeoxyglucose (FDG) in SCI rats
[40], whereas our study provides information on a specific
aspect of NI occurring after CNS injury, rather than a general
increase in metabolic activity. [18F]GE-180 PET data analysis/
CT imaging was able to detect specific SCI-related NI 7 days
after injury. This is a critical time for the macrophage/
microglia posttraumatic inflammatory wave [41] after SCI,
which in this model occurs at a time when there is ongoing
hind limb locomotor impairment [31]. This minimally inva-
sive imaging approach may allow serial monitoring of the
dynamics of NI using a marker that can already be used in
patients, and is thus clinically relevant [42, 43].
Another major use of TSPO imaging is to monitor the
effects of therapeutic interventions developed for CNS injury.
We therefore tested the use of [18F]GE-180 PET/CT imaging
in assessing the effect of DHA treatment, which has been
shown to have neuroprotective effects in CNS injury [26,
31] and stroke models [44, 45] . Studies have shown signifi-
cant functional recovery following administration of a single
acute intravenous dose of DHA after spinal injury in various
Fig. 7 Representative confocal images of the immunohistochemical
staining of spinal cord sections from SCI animals on day 7 after injury.
TSPO immunolabelling can mainly be seen in the edges of the lesion (a,
b), but also along the tissue extending from the injury site (arrowheads). a
Microglia (Iba-1) are seen in the centre of the lesion as well as in
surrounding tissue. Amoeboid and less-ramified microglia showing
TSPO labelling are seen closer to the injury edges (inset a and b) while
ramified microglia without or with limited TSPO labelling are seen in the
tissue extending away from the lesion edges (inset c). b GFAP
immunolabelling shows clear astroglial scar around the injury site.
TSPO immunolabelling can mainly be seen in the centre of the lesion
above the glial scar tissue (inset d)
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spinal injury models [30–32]. The effects of a single injection
of DHA delivered 30 min after injury are remarkably long-
lasting, and interestingly, when the single bolus DHA treat-
ment was delayed for 3 weeks or even 3 h after SCI, the
functional improvement is abolished [32, 45, 46].
Despite not being able to detect in vivo a significant in-
crease [18F]GE-180 uptake in the T10 region 7 days after
injury between the SCI-DHA animals and the SCI-saline an-
imals, there was an overall trend towards a lower tracer uptake
seen in the cumulative and dynamic emission PET scans (up-
take was 20 % higher in SCI-saline animals than in SCI-DHA
animals). This reduction in TSPO binding was better detected
in the ex vivo biodistribution study, with a decrease of about
30 % in TSPO binding after DHA treatment. Interestingly, the
autoradiography samples of the spinal cord from the SCI-
DHA animals showed an overall decrease in TSPO binding
across the whole spinal cord, including the T10 injured area,
compared with the signal seen in the SCI-saline animals. This
was confirmed by immunohistochemistry analysis showing
lower TSPO expression in the lesion centre in the SCI-DHA
animals compared with that in the SCI-saline animals (26 % in
SCI-DHA animals vs. 40 % in SCI-saline animals). This sig-
nificant reduction in [18F]GE-180 binding ex vivo supports
the potential diagnostic role of TSPO imaging for monitoring
NI modulatory treatments such as DHA.
DHA exerts protective effects in microglia and neurons by
maintaining, for example, the optimal size of lipid bodies,
which is markedly increased during NI [47]. Smaller lipid
bodies may be more mobile and effective in providing energy
to mitochondria, providing a restorative effect in mitochondri-
al metabolism. DHA has also been linked to a reduction in
oxidative phosphorylation, modulating mitochondrial respira-
tion and reducing oxidative stress after trauma [48]. TSPO has
been associated with many of these metabolic and cellular
respiratory functions, supporting its modulatory role during
NI, cell metabolism and cell death [49]. The mechanism in-
volved in the NI modulatory effect of DHA and how it affects
TSPO expression is not well understood and warrants further
research. Our data support the NI modulatory role of DHA on
day 7, yet TSPO uptake remained considerable in the SCI-
DHA animals compared with the naive animals (study 1).
Future longitudinal serial TSPO imaging studies on DHA-
treated SCI and naive animals may help to clarify the long-
term therapeutic impact of DHA treatment and its mechanisms
of action.
There is scarce information on the use of TSPO imaging for
monitoring therapeutic effects. Our observations support the
value of the novel ligand [18F]GE-180 for monitoring re-
sponse to treatment, as shown in a recent study which assessed
treatment effects in a preclinical model of progressive multiple
sclerosis [50]. Modulating glial activation and NI remains
critical in neurotrauma injury, and successful modulation of
NI may improve prognosis for tissue repair and regeneration
[51]. The work presented here supports the value of TSPO
PET imaging for assessing glial inflammatory response
in vivo, and its development as a surrogate marker for NI in
preclinical and clinical assessments. Despite specific limita-
tions of preclinical PET technology (spatial resolution around
1.35 mm), functional imaging holds great potential for trans-
lational SCI research, allowing in vivo longitudinal assess-
ment of disease progression, overcoming the cumbersome
and poorly translational histopathological assessments.
Furthermore, such imaging complements modalities such as
MRI and CT, and provides a detailed understanding of the
location and dynamics of the inflammatory response associat-
ed with spinal injury.
Imaging metabolic activity in SCI animals poses chal-
lenges, as their physiological impairment may affect radiotrac-
er uptake. In our study, SCI animals were severely impaired
(as confirmed by a BBB score of about 6.3±0.5) and showed
a decrease of about 20 % in body weight compared with the
LAM and naive animals, which is within the range for
contused SCI rat models during the first week after injury.
The body weight of the animals was accounted for and nor-
malized for tracer uptake quantification PET imaging analysis
(expressed as percent injected dose per gram; quantitative
analysis using SUVs showed similar differential uptake
among SCI, LAM and naive animals).
Another challenge for TSPO imaging of CNS injury is
associated with the lack of discrimination between the resident
microglia and the infiltrated peripherally derived macro-
phages. Both microglia and macrophages undergo
Bactivation^ in response to neuronal injury in a variety of
neurological disorders [52] and TSPO expression is highly
upregulated in both cell types [18]. Experimental approaches
using specifically labelled haematogenous macrophages in
knock-in mouse models [53], myeloablated and bone marrow
transplanted chimeric mice [54] and macrophages labelled
with paramagnetic iron oxide and monitoring cell trafficking
byMR imaging [55] have been used to characterize the role of
systemic inflammation during CNS injury. Some of these ap-
proaches could be used to clarify the TSPO pattern of expres-
sion in resident microglia in comparison with that in infiltrat-
ing macrophages present in the injured cord. Microglia play a
major role in the initial response to injury through phagocytic
processing of the inflamed and injured spine, while circulatory
macrophages may contribute to secondary damage and poor
long-term outcome after injury [46]. From a mechanistic path-
ophysiological approach, it would be interesting to differen-
tially image the TSPO expressed in microglia and those in
circulating macrophages, and to clarify whether this translates
into any specific clinical relevance that could affect outcomes
and specific treatments. Nevertheless, our findings should
open the way to develop new approaches for TSPO PET im-
aging as a diagnostic indicator of spinal inflammation after
traumatic injury, which should help elucidate the dynamics
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and role of different inflammatory cells during the acute and
chronic stages after injury.
Conclusion
We report here for the first time the imaging of NI in contused
spinal cords in a rat model using the novel [18F]GE-180 highly
TSPO-specific PET radioligand. These studies should provide
more insight into the preclinical and clinical relevance of
assessing NI in vivo and help define the role of increased
TSPO expression during CNS inflammation and repair.
Overall, TSPO PET imaging may provide new approaches
to improving translational research and the clinical manage-
ment of SCI patients.
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